Cargando…

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights

Combating acquired drug resistance of EGFR tyrosine kinase (TK) is a great challenge and an urgent necessity in the management of non-small cell lung cancers. The advanced EGFR (L858R/T790M/C797S) triple mutation has been recently reported, and there have been no specific drugs approved for this str...

Descripción completa

Detalles Bibliográficos
Autores principales: Suriya, Utid, Mahalapbutr, Panupong, Wimonsong, Watchara, Yotphan, Sirilata, Choowongkomon, Kiattawee, Rungrotmongkol, Thanyada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788584/
https://www.ncbi.nlm.nih.gov/pubmed/36558033
http://dx.doi.org/10.3390/molecules27248901
_version_ 1784858789489410048
author Suriya, Utid
Mahalapbutr, Panupong
Wimonsong, Watchara
Yotphan, Sirilata
Choowongkomon, Kiattawee
Rungrotmongkol, Thanyada
author_facet Suriya, Utid
Mahalapbutr, Panupong
Wimonsong, Watchara
Yotphan, Sirilata
Choowongkomon, Kiattawee
Rungrotmongkol, Thanyada
author_sort Suriya, Utid
collection PubMed
description Combating acquired drug resistance of EGFR tyrosine kinase (TK) is a great challenge and an urgent necessity in the management of non-small cell lung cancers. The advanced EGFR (L858R/T790M/C797S) triple mutation has been recently reported, and there have been no specific drugs approved for this strain. Therefore, our research aimed to search for effective agents that could impede the function of EGFR (L858R/T790M/C797S) TK by the integration of in silico and in vitro approaches. Our in-house quinoxalinone-containing compounds were screened through molecular docking and their biological activity was then verified by enzyme- and cell-based assay. We found that the four quinoxalinone-containing compounds including CPD4, CPD15, CPD16, and CPD21 were promising to be novel EGFR (L858R/T790M/C797S) TK inhibitors. The IC(50) values measured by the enzyme-based assay were 3.04 ± 1.24 nM; 6.50 ± 3.02 nM,10.50 ± 1.10 nM; and 3.81 ± 1.80 nM, respectively, which are at a similar level to a reference drug; osimertinib (8.93 ± 3.01 nM). Besides that, they displayed cytotoxic effects on a lung cancer cell line (H1975) with IC(50) values in the range of 3.47 to 79.43 μM. In this proposed study, we found that all screened compounds could interact with M793 at the hinge regions and two mutated residues including M790 and S797; which may be the main reason supporting the inhibitory activity in vitro. The structural dynamics revealed that the screened compounds have sufficient non-native contacts with surrounding amino acids and could be well-buried in the binding site’s cleft. In addition, all predicted physicochemical parameters were favorable to be drug-like based on Lipinski’s rule of five, and no extreme violation of toxicity features was found. Altogether, this study proposes a novel EGFR (L858R/T790M/C797S) TK inhibitor scaffold and provides a detailed understanding of compounds’ recognition and susceptibility at the molecular level.
format Online
Article
Text
id pubmed-9788584
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97885842022-12-24 Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights Suriya, Utid Mahalapbutr, Panupong Wimonsong, Watchara Yotphan, Sirilata Choowongkomon, Kiattawee Rungrotmongkol, Thanyada Molecules Article Combating acquired drug resistance of EGFR tyrosine kinase (TK) is a great challenge and an urgent necessity in the management of non-small cell lung cancers. The advanced EGFR (L858R/T790M/C797S) triple mutation has been recently reported, and there have been no specific drugs approved for this strain. Therefore, our research aimed to search for effective agents that could impede the function of EGFR (L858R/T790M/C797S) TK by the integration of in silico and in vitro approaches. Our in-house quinoxalinone-containing compounds were screened through molecular docking and their biological activity was then verified by enzyme- and cell-based assay. We found that the four quinoxalinone-containing compounds including CPD4, CPD15, CPD16, and CPD21 were promising to be novel EGFR (L858R/T790M/C797S) TK inhibitors. The IC(50) values measured by the enzyme-based assay were 3.04 ± 1.24 nM; 6.50 ± 3.02 nM,10.50 ± 1.10 nM; and 3.81 ± 1.80 nM, respectively, which are at a similar level to a reference drug; osimertinib (8.93 ± 3.01 nM). Besides that, they displayed cytotoxic effects on a lung cancer cell line (H1975) with IC(50) values in the range of 3.47 to 79.43 μM. In this proposed study, we found that all screened compounds could interact with M793 at the hinge regions and two mutated residues including M790 and S797; which may be the main reason supporting the inhibitory activity in vitro. The structural dynamics revealed that the screened compounds have sufficient non-native contacts with surrounding amino acids and could be well-buried in the binding site’s cleft. In addition, all predicted physicochemical parameters were favorable to be drug-like based on Lipinski’s rule of five, and no extreme violation of toxicity features was found. Altogether, this study proposes a novel EGFR (L858R/T790M/C797S) TK inhibitor scaffold and provides a detailed understanding of compounds’ recognition and susceptibility at the molecular level. MDPI 2022-12-14 /pmc/articles/PMC9788584/ /pubmed/36558033 http://dx.doi.org/10.3390/molecules27248901 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Suriya, Utid
Mahalapbutr, Panupong
Wimonsong, Watchara
Yotphan, Sirilata
Choowongkomon, Kiattawee
Rungrotmongkol, Thanyada
Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title_full Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title_fullStr Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title_full_unstemmed Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title_short Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
title_sort quinoxalinones as a novel inhibitor scaffold for egfr (l858r/t790m/c797s) tyrosine kinase: molecular docking, biological evaluations, and computational insights
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788584/
https://www.ncbi.nlm.nih.gov/pubmed/36558033
http://dx.doi.org/10.3390/molecules27248901
work_keys_str_mv AT suriyautid quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights
AT mahalapbutrpanupong quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights
AT wimonsongwatchara quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights
AT yotphansirilata quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights
AT choowongkomonkiattawee quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights
AT rungrotmongkolthanyada quinoxalinonesasanovelinhibitorscaffoldforegfrl858rt790mc797styrosinekinasemoleculardockingbiologicalevaluationsandcomputationalinsights